Malignant gliomas in adults.

Approximately 5% of patients with malignant gliomas have a family history of gliomas. Some of these familial cases are associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2, the Li−Fraumeni syndrome (germ-line p53 mutations associated with an increased risk of several cancers), and Turcot’s syndrome (intestinal polyposis and brain tumors). 10 However, most familial cases have

[1]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[2]  L. Deangelis,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[3]  R. McLendon,et al.  Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma , 2009, Cancer.

[4]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[5]  S. Nelson,et al.  Bevacizumab and chemotherapy for recurrent glioblastoma , 2009, Neurology.

[6]  R. Jain,et al.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.

[7]  Allan H Friedman,et al.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[9]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Wen New developments in targeted molecular therapies for glioblastoma , 2009, Expert review of anticancer therapy.

[11]  Henry Brem,et al.  Central nervous system cancers. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.

[14]  P. Wen,et al.  Antiangiogenic therapy in malignant gliomas , 2008, Current opinion in oncology.

[15]  L. Ellis,et al.  Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.

[16]  D. Bigner,et al.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. , 2008, Seminars in immunology.

[17]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[19]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[20]  K. Hoang-Xuan,et al.  Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. , 2008, The oncologist.

[21]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[23]  T. Cloughesy,et al.  Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. , 2008, International journal of radiation oncology, biology, physics.

[24]  Susan M. Chang,et al.  Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. , 2008, Neuro-oncology.

[25]  K. Aldape,et al.  Molecular predictors in glioblastoma: toward personalized therapy. , 2008, Archives of neurology.

[26]  D. Rowitch,et al.  Glioma Stem Cells: A Midterm Exam , 2008, Neuron.

[27]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Dirks,et al.  Brain tumor stem cells: bringing order to the chaos of brain cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Bigner,et al.  Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM , 2008 .

[30]  G. Johnson,et al.  Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival , 2008 .

[31]  T. Mikkelsen,et al.  A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .

[32]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM) , 2008 .

[33]  W. Mason,et al.  The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma , 2008 .

[34]  T. Mikkelsen,et al.  Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan , 2008 .

[35]  H. Friedman,et al.  Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas , 2008 .

[36]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[37]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[38]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[39]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[40]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[41]  T. MacDonald,et al.  Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report , 2007, Clinical Cancer Research.

[42]  M. Bent Anaplastic oligodendroglioma and oligoastrocytoma. , 2007 .

[43]  P. Wen,et al.  Inhibition of angiogenesis and invasion in malignant gliomas , 2007, Expert review of anticancer therapy.

[44]  D. Gutmann,et al.  Cancer stem cells and brain tumors: uprooting the bad seeds , 2007, Expert review of anticancer therapy.

[45]  S. Plotkin,et al.  Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. , 2007, Neurologic clinics.

[46]  Volker W Stieber,et al.  Advances in radiation therapy for brain tumors. , 2007, Neurologic clinics.

[47]  D. Reardon,et al.  Diagnosis and treatment of high-grade astrocytoma. , 2007, Neurologic clinics.

[48]  N. Pouratian,et al.  Advances in brain tumor surgery. , 2007, Neurologic clinics.

[49]  Margaret Wrensch,et al.  Epidemiology of brain tumors. , 2007, Neurologic clinics.

[50]  Geoffrey S Young,et al.  Advanced MRI of adult brain tumors. , 2007, Neurologic clinics.

[51]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[52]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  E. Linos,et al.  Atopy and risk of brain tumors: a meta-analysis. , 2007, Journal of the National Cancer Institute.

[54]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[55]  Robert T Abraham,et al.  Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.

[56]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[57]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[58]  Christopher G Willett,et al.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  L. Leibovici,et al.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. , 2007, Mayo Clinic proceedings.

[61]  S. Shete,et al.  GLIOGENE—an International Consortium to Understand Familial Glioma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[62]  Wei Chen Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.

[63]  N. Curtin,et al.  PARP inhibitor development for systemic cancer targeting. , 2007, Anti-cancer agents in medicinal chemistry.

[64]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[66]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[67]  D. Reardon,et al.  Molecularly targeted therapy for malignant glioma , 2007, Cancer.

[68]  P. Wen,et al.  A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma , 2007 .

[69]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  V. Collins,et al.  Mechanisms of Disease: genetic predictors of response to treatment in brain tumors , 2007, Nature Clinical Practice Oncology.

[71]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[72]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[73]  P. Wen,et al.  The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. , 2007, Journal of the National Cancer Institute.

[74]  Anssi Auvinen,et al.  Mobile phone use and risk of glioma in 5 North European countries , 2007, International journal of cancer.

[75]  D. Hicklin,et al.  Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. , 2007, Cancer research.

[76]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[77]  Kjell Hansson Mild,et al.  Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years , 2007, Occupational and Environmental Medicine.

[78]  M. Lesniak,et al.  Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. , 2007, Current drug delivery.

[79]  P. Wen,et al.  Inhibiting kinases in malignant gliomas , 2007, Expert opinion on therapeutic targets.

[80]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[81]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[82]  G. Fulci,et al.  The status of gene therapy for brain tumors , 2007, Expert opinion on biological therapy.

[83]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[84]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[85]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[86]  R. McLendon,et al.  Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas , 2007, Journal of Neuro-Oncology.

[87]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[88]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[89]  C. Marras,et al.  Glioblastoma‐derived tumorospheres identify a population of tumor stem‐like cells with angiogenic potential and enhanced multidrug resistance phenotype , 2006, Glia.

[90]  S. Gabriel,et al.  Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.

[91]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[92]  A. Brandes,et al.  Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[94]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[95]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[96]  M. Gonda,et al.  Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Susan M. Chang,et al.  Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  S. Kesari,et al.  The Bad Seed: PDGF Receptors Link Adult Neural Progenitors to Glioma Stem Cells , 2006, Neuron.

[99]  P. Wen,et al.  Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.

[100]  M. Assanah,et al.  Glial Progenitors in Adult White Matter Are Driven to Form Malignant Gliomas by Platelet-Derived Growth Factor-Expressing Retroviruses , 2006, The Journal of Neuroscience.

[101]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  B. Fox,et al.  Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer , 2006, Cancer Gene Therapy.

[104]  Angelo L. Vescovi,et al.  Brain tumour stem cells , 2006, Nature Reviews Cancer.

[105]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[106]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[107]  K. Aldape,et al.  Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. , 2006, Cancer research.

[108]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[109]  E. Shaw,et al.  Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Susan M. Chang,et al.  Diagnosis and treatment of recurrent high-grade astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  D. Gerber,et al.  Management of venous thromboembolism in patients with primary and metastatic brain tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[113]  S. Cha,et al.  Update on brain tumor imaging: from anatomy to physiology. , 2006, AJNR. American journal of neuroradiology.

[114]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[115]  R. Martuza,et al.  Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.

[116]  A. Verma MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[117]  R. Coleman,et al.  Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  V. Levin,et al.  Headache related to brain tumors , 2006, Current treatment options in neurology.

[119]  Z. Ram,et al.  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.

[120]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  J. Debus,et al.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[123]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  M. Berger,et al.  Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors , 2005, Cell cycle.

[125]  R. Arusell,et al.  A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival , 2005, Neurosurgery.

[126]  J. Flickinger,et al.  The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. , 2005, International journal of radiation oncology, biology, physics.

[127]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[128]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[130]  M. Andreeff,et al.  Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. , 2005, Cancer research.

[131]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[132]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[133]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[134]  M. Vogelbaum,et al.  Results of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain Tumors , 2005, Journal of Neuro-Oncology.

[135]  Maria Werner-Wasik,et al.  Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.

[136]  Caterina Giannini,et al.  Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.

[137]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  E. Laws,et al.  Depression in Patients with High-grade Glioma: Results of the Glioma Outcomes Project , 2004, Neurosurgery.

[139]  Susan M. Chang,et al.  Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.

[140]  M. Gilbert,et al.  Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. , 2004, Neuro-oncology.

[141]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[143]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  S. Spencer,et al.  Role of Radiation Therapy and Radiosurgery in Glioblastoma Multiforme , 2003, Cancer journal.

[145]  L. Recht,et al.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas , 2003, Cancer.

[146]  W. Cavenee,et al.  Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. , 2003, The American journal of pathology.

[147]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[148]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[149]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[150]  M. Westphal,et al.  Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.

[151]  J. Olson,et al.  The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. , 2002, Neurosurgery.

[152]  J. Olson,et al.  The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine , 2002, Neurosurgery.

[153]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[154]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[155]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[156]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[157]  Z L Gokaslan,et al.  Limitations of stereotactic biopsy in the initial management of gliomas. , 2001, Neuro-oncology.

[158]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[159]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[160]  A. Brandes,et al.  Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of Oncology.

[161]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[162]  M. member Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[163]  P. Black,et al.  Cellular-telephone use and brain tumors. , 2001, The New England journal of medicine.

[164]  H. Engelhard,et al.  Gene therapy for brain tumors , 2000, Current oncology reports.

[165]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[166]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[167]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[168]  L. Recht,et al.  Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors , 2000, Neurology.

[169]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[172]  M. Westphal,et al.  Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis , 1999, International journal of cancer.

[173]  M. Martel,et al.  Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.

[174]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[175]  V. Levin,et al.  Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  D. Louis,et al.  SPECIFIC CHROMOSOMAL LOSSES PREDICT CHEMOTHERAPEUTIC RESPONSE AND SURVIVAL IN PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMAS , 1998 .

[177]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[178]  A. Hopkins,et al.  Malignant cerebral glioma—I: Survival, disability, and morbidity after radiotherapy , 1996, BMJ.

[179]  Y. Yonekawa,et al.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.

[180]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[181]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[182]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[183]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[184]  P. Graham Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[185]  P. Wen,et al.  Complications of therapy for venous thromboembolic disease in patients with brain tumors , 1993, Neurology.

[186]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[187]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[188]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[189]  S. Weiss,et al.  Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. , 1992, Science.

[190]  D. Stefanik,et al.  Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. , 1991, Cancer research.

[191]  R. Ruff,et al.  Incidence and treatment of peripheral venous thrombosis in patients with glioma , 1983, Annals of neurology.

[192]  K. Takakura,et al.  [Epidemiology of brain tumors (author's transl)]. , 1982, No to shinkei = Brain and nerve.

[193]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[194]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[195]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.